AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25609353 — intervention group
Group type: COMPARATOR
Intervention: Positive double-blind, placebo-controlled food challenge
Number of subjects: 74
Study 25609353 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall symptoms during positive OFCs
Number of subjects: 74
Study 25609400 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 2509
Study 25609400 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2509
Study 25609545 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 17
Study 25609942 — intervention group
Group type: EXPERIMENTAL
Intervention: eDiary intervention
Number of subjects: 209
Study 25610763 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptom severity
Number of subjects: 57
Study 25610980 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD patients (sleepy group, 0-19 min)
Number of subjects: 59
Study 25610980 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD patients (intermediate group, 20-33 min)
Number of subjects: 59
Study 25610980 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD patients (alert group, 34-40 min)
Number of subjects: 59
Study 25610980 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD patients
Number of subjects: 59
Study 25610980 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 59
Study 25610980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleepy ADHD patients
Number of subjects: 59
Study 25611227 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Number of subjects: 138
Study 25611227 — intervention group
Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 138
Study 25611568 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA with OD > 1.00
Number of subjects: 496
Study 25611568 — intervention group
Group type: COMPARATOR
Intervention: ELISA with OD > 0.40
Number of subjects: 496
Study 25611568 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold optical density (OD) > 1.00
Number of subjects: 496
Study 25611808 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound (US) examinations by nurses using a pocket-size imaging device (PSID) after a 3-month training period.
Number of subjects: 59
Study 25612228 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT)
Number of subjects: 768
Study 25612228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical COPD Questionnaire (CCQ)
Number of subjects: 768
Study 25612228 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Medical Research Council (mMRC) dyspnea scores
Number of subjects: 768
Study 25612228 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for CAT
Number of subjects: 768
Study 25612228 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for CCQ
Number of subjects: 768
Study 25612228 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for mMRC dyspnea scores
Number of subjects: 768
Study 25612228 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds for CAT and CCQ scores
Number of subjects: 768
Study 25612623 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT)
Number of subjects: 27
Study 25612623 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to zoledronic acid (ZOL)
Number of subjects: 27
Study 25612635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 60 mg/m(2)/week on days 1, 8, 22, and 29 plus S-1 80 mg/m(2)/day on days 1-5, 8-12, 22-27, and 29-33 with 50.4 Gy radiotherapy
Number of subjects: 13
Study 25613108 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP and echocardiographic measurements (algorithm including BNP, DLCO, and echocardiography)
Number of subjects: 113
Study 25613108 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP in catheterized patients with invasive PAPs > 40 mm Hg
Number of subjects: 113
Study 25613108 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP in catheterized patients with Wedge pressure > 14 mm Hg
Number of subjects: 113
Study 25613108 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm including BNP, DLCO, and echocardiography
Number of subjects: 113
Study 25613115 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth quartile of serum CRP
Number of subjects: 1514
Study 25613115 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth quartile of serum CRP in men
Number of subjects: 1514
Study 25613115 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth quartile of serum CRP in women
Number of subjects: 1514
Study 25613115 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum CRP concentrations
Number of subjects: 1514
Study 25613340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 154
Study 25613340 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral warming
Number of subjects: 154
Study 25613340 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise
Number of subjects: 154
Study 25613340 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 154
Study 25613340 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of fasting and warming
Number of subjects: 154
Study 25613597 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal Ideation (SI) in the past 2 weeks (measured by 9-item Patient Health Questionnaire)
Number of subjects: 2533
Study 25613597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime Suicide Attempts (SA)
Number of subjects: 2533
Study 25613597 — intervention group
Group type: EXPERIMENTAL
Intervention: Current level of depression
Number of subjects: 2533
Study 25613597 — intervention group
Group type: EXPERIMENTAL
Intervention: Less education, younger age at injury, current or past treatment of depression, bipolar disorder or schizophrenia
Number of subjects: 2533
Study 25613597 — intervention group
Group type: EXPERIMENTAL
Intervention: More years since injury, lifetime SA
Number of subjects: 2533
Study 25613597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower environmental reward and less positive affect
Number of subjects: 2533
Study 25613597 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of one's community activities and spiritual well-being
Number of subjects: 2533
Study 25613597 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of SCI
Number of subjects: 2533
Study 25613716 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa booster dose (0.5mg or 0.3mg formulations)
Number of subjects: 478
Study 25613716 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa booster dose (0.133mg group received 0.5mg formulation)
Number of subjects: 478
Study 25613716 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa booster dose
Number of subjects: 478
Study 25614165 — intervention group
Group type: EXPERIMENTAL
Intervention: IW001 (col(V) oral immunotherapeutic)
Number of subjects: 30
Study 25614256 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radical prostatectomy (RP) after focal VTP treatment
Number of subjects: 19
Study 25614280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly subcutaneous
Number of subjects: 382
Study 25614280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 25614467 — intervention group
Group type: COMPARATOR
Intervention: Curative surgical resection alone
Number of subjects: 2783
Study 25614467 — intervention group
Group type: COMPARATOR
Intervention: Curative surgical resection alone with more than two poor risk factors
Number of subjects: 2783
Study 25614467 — intervention group
Group type: COMPARATOR
Intervention: Curative surgical resection alone with fewer than two poor risk factors
Number of subjects: 2783
Study 25614734 — intervention group
Group type: EXPERIMENTAL
Intervention: PGC1α -1 nucleosome position (UP vs DN)
Number of subjects: 0
Study 25614734 — intervention group
Group type: EXPERIMENTAL
Intervention: NTPGC1α splice variant expression
Number of subjects: 0
Study 25614940 — intervention group
Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 0
Study 25614940 — intervention group
Group type: EXPERIMENTAL
Intervention: new agents under investigation
Number of subjects: 0
Study 25614962 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60 mg plus Sofosbuvir (SOF) 400 mg once-daily for 12 weeks
Number of subjects: 152
Study 25614962 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus Sofosbuvir (SOF)
Number of subjects: 152
Study 25616099 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 c.3435TT genotype
Number of subjects: 115
Study 25616099 — intervention group
Group type: COMPARATOR
Intervention: ABCB1 c.2677GT and 2677TT genotypes
Number of subjects: 115
Study 25616099 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 c.2677TT genotype
Number of subjects: 115
Study 25616495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity physical activity
Number of subjects: 123
Study 25616495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 123
Study 25616495 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of steps on weekdays
Number of subjects: 123
Study 25616495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity physical activity on weekdays
Number of subjects: 123
Study 25616495 — intervention group
Group type: COMPARATOR
Intervention: Physical activity and sedentary behavior by sex, BMI, motor skills, or family-related variables
Number of subjects: 123
Study 25616558 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based coagulation service
Number of subjects: 2771
Study 25616558 — intervention group
Group type: COMPARATOR
Intervention: Regular medical care
Number of subjects: 2771
Study 25616558 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation service (follow-up of patients from regular medical care)
Number of subjects: 2771
Study 25616577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 50
Study 25616577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25616752 — intervention group
Group type: EXPERIMENTAL
Intervention: pCLE with ERCP
Number of subjects: 136
Study 25616752 — intervention group
Group type: COMPARATOR
Intervention: Tissue sampling alone
Number of subjects: 136
Study 25616752 — intervention group
Group type: EXPERIMENTAL
Intervention: After tissue sampling
Number of subjects: 136
Study 25616819 — intervention group
Group type: EXPERIMENTAL
Intervention: New permanent pacemaker (PPM) implantation after TAVR
Number of subjects: 1973
Study 25616819 — intervention group
Group type: EXPERIMENTAL
Intervention: New PPM
Number of subjects: 1973
Study 25616922 — intervention group
Group type: EXPERIMENTAL
Intervention: Early angiography (<2 h) after fibrinolysis
Number of subjects: 1238
Study 25616922 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography within 4 h after fibrinolysis
Number of subjects: 1238
Study 25616922 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter symptom onset to angiography time (<4 h)
Number of subjects: 1238
Study 25616922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis to angiography time
Number of subjects: 1238
Study 25616922 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom onset to angiography time
Number of subjects: 1238
Study 25616922 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing fibrinolysis to angiography time
Number of subjects: 1238
Study 25616922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis to angiography time and symptom onset to angiography time
Number of subjects: 1238
Study 25617154 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized yoga conducted three times weekly for three weeks.
Number of subjects: 11
Study 25617726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone treatment for four weeks
Number of subjects: 9
Study 25617726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone treatment
Number of subjects: 9
Study 25617726 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 9
Study 25617915 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding metallic stent (SEMS) insertion, n = 38
Number of subjects: 2944
Study 25619574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated endografts
Number of subjects: 0
Study 25620457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortrosyn(™) stimulated aldosterone level of 5 ng/dl (0·14 nmol/l)
Number of subjects: 101
Study 25620457 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine sodium levels
Number of subjects: 101
Study 25620457 — intervention group
Group type: COMPARATOR
Intervention: Posture (sitting or semifowlers)
Number of subjects: 101
Study 25620668 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule colonoscopy
Number of subjects: 884
Study 25620753 — intervention group
Group type: EXPERIMENTAL
Intervention: Six or more eating occasions in 24 hours
Number of subjects: 2696
Study 25620753 — intervention group
Group type: COMPARATOR
Intervention: Fewer than four eating occasions in 24 hours
Number of subjects: 2696
Study 25621498 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced decitabine dosages (0.1-0.2 mg/kg/day)
Number of subjects: 25
Study 25622055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus peginterferon-ribavirin for 12 weeks
Number of subjects: 23
Study 25622055 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir
Number of subjects: 23
Study 25622640 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS-IL2 (0.15 mg/kg, 0.30 mg/kg, 0.45 mg/kg) plus radiotherapy (5x 4 Gy)
Number of subjects: 13
Study 25622640 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS-IL2 alone (5 mg/kg; days 7-9) plus fractionated radiotherapy (3.6 Gy; days 0-4) plus cisplatin (4 mg/kg; day 0)
Number of subjects: 13
Study 25622723 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunophenotyping analysis of leukocytes from induced sputum, bronchoalveolar lavage (BAL), and peripheral blood.
Number of subjects: 300
Study 25622723 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunophenotyping analysis using 12-color antibody panels.
Number of subjects: 300
Study 25622723 — intervention group
Group type: EXPERIMENTAL
Intervention: Study design with bi-directional communication between clinical centers and the Core.
Number of subjects: 300
Study 25622919 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (10 mg) intravenous injection
Number of subjects: 21
Study 25622919 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Sudomotor Axon Reflex Test (QSART)
Number of subjects: 21
Study 25622919 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying tests
Number of subjects: 21
Study 25622919 — intervention group
Group type: COMPARATOR
Intervention: Orthostatic and edrophonium tests
Number of subjects: 21
Study 25623151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal evaporative cooling
Number of subjects: 28
Study 25624131 — intervention group
Group type: COMPARATOR
Intervention: 6 SQ-HDM
Number of subjects: 604
Study 25624131 — intervention group
Group type: COMPARATOR
Intervention: 1 SQ-HDM
Number of subjects: 604
Study 25624131 — intervention group
Group type: COMPARATOR
Intervention: 3 SQ-HDM
Number of subjects: 604
Study 25624131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 25624177 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and radiation
Number of subjects: 0
Study 25624326 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) with twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV)
Number of subjects: 24
Study 25624326 — intervention group
Group type: COMPARATOR
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 24
Study 25624327 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isavuconazole (400/200/200 mg loading doses on day 1 and 200/200 mg on day 2, followed by 200 mg once daily for days 3 to 28)
Number of subjects: 24
Study 25624327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose isavuconazole (doses doubled from low-dose regimen)
Number of subjects: 24
Study 25624327 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment success
Number of subjects: 24
Study 25624403 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (ARA) 10 mg/kg per day for 15 days
Number of subjects: 268
Study 25624403 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) 40 mg/kg single dose
Number of subjects: 268
Study 25624403 — intervention group
Group type: EXPERIMENTAL
Intervention: PZQ combined with ARA
Number of subjects: 268
Study 25624403 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical and immunological profiles after ARA therapy
Number of subjects: 268
Study 25624439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported toxicity
Number of subjects: 1090
Study 25624439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported toxicity (very much severity)
Number of subjects: 1090
Study 25624439 — intervention group
Group type: COMPARATOR
Intervention: Physician-reported toxicity
Number of subjects: 1090
Study 25624441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine (MP)
Number of subjects: 1028
Study 25624441 — intervention group
Group type: EXPERIMENTAL
Intervention: TPMT or NUDT15 variants (homozygous or heterozygous)
Number of subjects: 1028
Study 25624441 — intervention group
Group type: COMPARATOR
Intervention: Others (not homozygous for TPMT or NUDT15 variants)
Number of subjects: 1028
Study 25625006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Flute
Number of subjects: 69
Study 25625006 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study 25625990 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient clinic for substance abuse
Number of subjects: 155
Study 25626035 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted MR/ultrasound fusion biopsy
Number of subjects: 1003
Study 25626035 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 1003
Study 25626035 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined targeted and standard biopsy
Number of subjects: 1003
Study 25626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.5 and 3 Hz) applied to the bladder dome
Number of subjects: 10
Study 25626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.5 and 3 Hz) applied to the trigone
Number of subjects: 10
Study 25626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.5 and 3 Hz) applied to the proximal urethra
Number of subjects: 10
Study 25626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.5 and 3 Hz) applied to the distal urethra
Number of subjects: 10
Study 25626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of age correlation with CPT/dome
Number of subjects: 10
Study 25626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of age correlation with N1 latency/dome
Number of subjects: 10
Study 25626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of age correlation with N1P2 amplitude/dome
Number of subjects: 10
Study 25626801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cryotherapy using CryoShape device
Number of subjects: 27
Study 25626801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cryotherapy
Number of subjects: 27
Study 25627002 — intervention group
Group type: EXPERIMENTAL
Intervention: IMO-2055 (0.16 mg/kg)
Number of subjects: 15
Study 25627002 — intervention group
Group type: EXPERIMENTAL
Intervention: IMO-2055 (0.32 mg/kg)
Number of subjects: 15
Study 25627002 — intervention group
Group type: EXPERIMENTAL
Intervention: IMO-2055 (0.48 mg/kg)
Number of subjects: 15
Study 25627002 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI/cetuximab (combined with IMO-2055)
Number of subjects: 15
Study 25627002 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI/cetuximab
Number of subjects: 15
Study 25627020 — intervention group
Group type: EXPERIMENTAL
Intervention: boceprevir
Number of subjects: 2084
Study 25627020 — intervention group
Group type: EXPERIMENTAL
Intervention: telaprevir
Number of subjects: 2084
Study 25627429 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood methods assuming masked missing not at random
Number of subjects: 0
Study 25627429 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood assuming masked missing not at random
Number of subjects: 0
Study 25627429 — intervention group
Group type: COMPARATOR
Intervention: Missing at random analysis
Number of subjects: 0
Study 25627429 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked missing not at random estimates
Number of subjects: 0
Study 25627936 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Family Doctors (RFD)
Number of subjects: 3148
Study 25627936 — intervention group
Group type: COMPARATOR
Intervention: Other Regular Doctors (ORD)
Number of subjects: 3148
Study 25627936 — intervention group
Group type: COMPARATOR
Intervention: No Regular Doctors (NRD)
Number of subjects: 3148
Study 25628001 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to air pollution (measured by personal NO2 levels)
Number of subjects: 25
Study 25628179 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (replacing 1 h·d(-1) of sitting with exercise)
Number of subjects: 154614
Study 25628179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexercise activities (replacing 1 h·d(-1) of sitting with nonexercise activities)
Number of subjects: 154614
Study 25628179 — intervention group
Group type: EXPERIMENTAL
Intervention: Purposeful exercise (replacing sitting time with exercise)
Number of subjects: 154614
Study 25628179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexercise activity (replacing sitting time with nonexercise activities)
Number of subjects: 154614
Study 25628404 — intervention group
Group type: EXPERIMENTAL
Intervention: IV thrombolysis (IVT)
Number of subjects: 1386
Study 25628520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein (n=53)
Number of subjects: 161
Study 25628520 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (n=54)
Number of subjects: 161
Study 25628520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=54)
Number of subjects: 161